Mitochondrial translocation of p210 BCR-ABL rewires downstream signaling by selectively suppressing ERK activation
Biochemical and Biophysical Research Communications · 2026-09 · 829 · 154168
DOI: 10.1016/j.bbrc.2026.154168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-09. Verfasst von Yuta Okuda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Life Sciences, Graduate School of Life and Medical Sciences, Doshisha University, Kyoto, 610-0394, Japan. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Mitochondria, Extracellular Signal-Regulated MAP Kinases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the fusion protein p210 BCR-ABL. In addition to activating canonical cytosolic signaling pathways, p210 BCR-ABL has been shown to translocate to the mitochondria upon mitochondrial damage through the interaction between its pleckstrin homology domain and cardiolipin, a mitochondria-specific phospholipid. We recently demonstrated that a fraction of p210 BCR-ABL localizes to the mitochondria in CML cells and promotes cell survival through mitochondria-associated signaling. However, whether mitochondria translocation of p210 BCR-ABL affects the major downstream signaling pathways activated by p210 BCR-ABL remains unclear. Here, we investigated the effects of mitochondrial translocation of p210-BCR-ABL on the JAK2/STAT5-, PI3K/AKT-, and RAS/MAPK-pathways using HEK293T cells expressing p210 BCR-ABL. Carbonyl cyanide m-chlorophenylhydrazone (CCCP), which induces mitochondrial damage and subsequent mitochondrial translocation of p210 BCR-ABL, markedly reduced ERK activation, whereas STAT5 and AKT activation were largely unaffected. Consistently, phosphorylation of SHC1, an adaptor protein directly phosphorylated by p210 BCR-ABL and required to ERK activation, was also suppressed by CCCP treatment. In contrast, CCCP did not affect EGF-induced ERK activation, indicating that the observed effect was specific for p210 BCR-ABL signaling. Moreover, N-acetylcysteine inhibited CCCP-induced reactive oxygen species production, prevented mitochondrial translocation of p210 BCR-ABL, and fully restored ERK-activation. These findings suggest that intercellular relocation of p210 BCR-ABL dynamically rewires downstream signaling networks, potentially optimizing the signaling balance required for CML cell survival and proliferation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Life Sciences, Graduate School of Life and Medical Sciences, Doshisha University, Kyoto, 610-0394, Japan.
- Department of Molecular Life Sciences, Graduate School of Life and Medical Sciences, Doshisha University, Kyoto, 610-0394, Japan. Electronic address: knishika@mail.doshisha.ac.jp.
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
Zitieren
APA
Okuda, Y., Watanabe-Takahashi, M., & Nishikawa, K. (2026). Mitochondrial translocation of p210 BCR-ABL rewires downstream signaling by selectively suppressing ERK activation. Biochemical and Biophysical Research Communications, 829, 154168. https://doi.org/10.1016/j.bbrc.2026.154168
Vancouver
Okuda Y, Watanabe-Takahashi M, Nishikawa K. Mitochondrial translocation of p210 BCR-ABL rewires downstream signaling by selectively suppressing ERK activation. Biochemical and Biophysical Research Communications. 2026;829:154168. doi:10.1016/j.bbrc.2026.154168
BibTeX
@article{Okuda2026,
author = {Okuda, Yuta and Watanabe-Takahashi, Miho and Nishikawa, Kiyotaka},
title = {Mitochondrial translocation of p210 BCR-ABL rewires downstream signaling by selectively suppressing ERK activation},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
volume = {829},
pages = {154168},
doi = {10.1016/j.bbrc.2026.154168}
}
EUVIMED